Pluronic® block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 19, Issue 1, 2002, Pages 1-72

  Kabanov, Alexander V ^a   Alakhov, Valery Yu ^b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b Supratek Pharma Inc   (Canada)

Author keywords

Block copolymers; Blood brain barrier; Cancer chemotherapy; Drug delivery; Gene therapy

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; COPOLYMER; DIGOXIN; DOXORUBICIN; ETOPOSIDE; EXCIPIENT; FLUORESCEIN; LOPERAMIDE; MANNITOL; METHOTREXATE; PACLITAXEL; PLURONIC F108; PLURONIC F127; PLURONIC F87; PLURONIC F88; PLURONIC F98; PLURONIC L101; PLURONIC L121; PLURONIC L35; PLURONIC L43; PLURONIC L44; PLURONIC L62; PLURONIC L92; PLURONIC P103; PLURONIC P104; PLURONIC P105; PLURONIC P123; PLURONIC P84; PLURONIC P85; POLOXAMER; RHODAMINE 123; RITONAVIR; VALPROIC ACID; VINBLASTINE; ZIDOVUDINE; ANTINEOPLASTIC AGENT; DRUG; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MEDICAL LITERATURE; MICELLE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TRANSGENE; BIOAVAILABILITY; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL RESPONSE MODIFIERS; BLOOD-BRAIN BARRIER; CLINICAL TRIALS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; EXCIPIENTS; GENE THERAPY; HUMANS; MICELLES; PHARMACEUTICAL PREPARATIONS; POLOXAMER; TISSUE DISTRIBUTION;

EID: 0036000109     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10     Document Type: Review

References (332)

1. Drug delivery and targeting
2. Use of vitamin B12 conjugates to deliver protein drugs by the oral route
3. Special issue: Polymeric micelles in biology and pharmaceutics, colloids and surfaces
4. Water-soluble polymers in medicine
5. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer
6. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles: Micelles as microcontainers for drug targeting
7. Block copolymers as drug carriers
8. Block copolymer micelles as long-circulating drug vehicles
9. Long circulating microparticulate drug carriers
10. Block copolymer micelles (microcontainers for drug targeting)
11. Site specific drug carriers: Polymeric micelles as high potential vehicles for biologically active molecules
12. Block copolymeric biotransport carriers as versatile vehicles for drug delivery
13. Soluble self-assembled block copolymers for drug delivery
14. Nano-engineering block copolymer aggregates for drug delivery
15. A review of block polymer surfactants
16. Perfluorochemicals as oxygen transport vehicles
17. Adjuvant formulations and their mode of action
18. Physical basis for poloxamer interactions
19. Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics
20. Use of nonionic block copolymers in vaccines and therapeutics
21. Block copolymers in pharmaceutics
22. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine
23. Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels
24. Comparison of lidocaine release from Pluronic F-127 gels and other formulations
25. Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel
26. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment
27. Inulin disposition following intramuscular administration of an inulin/poloxamer gel matrix
28. Sustained-release of urease from a poloxamer gel matrix
29. Ocular toxicity of vitreal pluronic polyol F-127
30. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice
31. Pharmacokinetic studies of methotrexate in plasma and synovial fluid following iv bolus and topical routes of administration in dogs
32. Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block
33. Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers
34. Vascular effects of sustained-release fibroblast growth factors
35. Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide
36. Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels
37. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use
38. Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms
39. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle
40. Micellization and gelation in block copolymer systems containing local anesthetics
41. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat
42. Enhanced rectal absorption of insulin-loaded Pluronic F-127 gels containing unsaturated fatty acids
43. Sustained-release interleukin-2 following intramuscular injection in rats
44. Diffusion of rat atrial natriuretic factor in thermoreversible poloxamer gels
45. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: Modulation by poloxamer 407 and implications for cardiovascular gene therapy
46. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors
47. Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels
48. Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent
49. Enhanced nasal retention of hydrophobically modified polyelectrolytes
50. Bioactive surfaces via immobilization of self-assembling polymers onto hydrophobic materials
51. Stabilization of water/oil/water multiple emulsions by polymerization of the aqueous phases
52. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes
53. Artificial blood emulsifiers
54. "Bloodless" rats through the use of artificial blood substitutes
55. Preparation of perfluorodecalin emulsion, an approach to the red cells substitute
56. Emulsions of perfluorinated solvents for intravascular gas transport
57. Efficacy of perfluorodecalin as an oxygen carrier for mouse and rat testes perfused in vitro
58. Effects of emulsified perfluorochemicals on liver cytochromes P-450 in rats
59. Oxygen-transport fluid based on perfluorochemicals: Effects on liver biochemistry
60. Role of perfluorochemical emulsions in the treatment of myocardial reperfusion injury
61. Perfluorocarbons as blood substitutes: The early years. Experience with Fluosol DA-20% in the 1980s
62. Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis
63. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%
64. Limitation of complement activation by perfluorocarbon emulsions: Superiority of lecithin-emulsified preparations
65. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration
66. The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338)
67. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes
68. Poloxamer-188 revisited: A potentially valuable immune modulator
69. Modification of the copolymers poloxamer 407 and poloxamine 908 can affect the physical and biological properties of surface modified nanospheres
70. Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: Applications in cancer drug delivery and imaging
71. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation
72. In vivo evaluation of protein adsorption to sterically stabilised colloidal carriers
73. Influence of block copolymers on the adsorption of plasma proteins to microspheres
74. In vitro displacement by rat serum of adsorbed radiolabeled poloxamer and poloxamine copolymers from model and biodegradable nanospheres
75. Neutrophil activation by plasma opsonized polymeric microspheres: Inhibitory effect of pluronic F127
76. Steric stabilization of microspheres with grafted polyethylene oxide reduces phagocytosis by rat Kupffer cells in vitro
77. Influence of surface coverage with poly(ethylene oxide) on attachment of sterically stabilized microspheres to rat Kupffer cells in vitro
78. The polyoxyethylene/polyoxypropylene block copolymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow
79. Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers
80. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation
81. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance
82. Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity
83. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers
84. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity
85. The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces
86. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity
87. Histamine release from human basophils by synthetic block co-polymers composed of polyoxyethylene and polyoxypropylene and synergywith immunologic and non-immunologic stimuli
88. In vitro release of histamine from murine mast cells by block co-polymers composed polyoxypropylene
89. Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle
90. Induction of macrophage Ia expression in vivo by a synthetic block copolymer, L81
91. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody
92. Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors
93. Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine
94. Mechanisms of action of nonionic block copolymer adjuvants
95. Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways
96. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of hightiter, long-lasting, cross-reactive antibodies of broad isotype
97. Artificial skin. I. Preparation and properties ofpluronic F-127 gels for treatment of burns
98. Pharmacokinetics of a new skin wound cleanser
99. Pluronic F-68: A promising new skin wound cleanser
100. Pluronic F-127 gel preparation as an artificial skin in the treatment of third-degree burns in pigs
101. A new silver sulfadiazine water soluble gel
102. Role of poloxamer 188 during recovery from ischemic spinal cord injury: A preliminary study
103. An amorphous hydrogel enhances epithelialisation of wounds
104. Tissue-engineered nipple reconstruction
105. Reduction of postoperative adhesions in the rat uterine horn model with poloxamer 407
106. Effect of a composite membrane of chitosan and poloxamer gel on postoperative adhesive interactions
107. Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock
108. Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries
109. Surfactant sealing of membranes permeabilized byionizing radiation
110. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots
111. Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model
112. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 NF), a hemorheological agent that alters neutrophil function
113. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial
114. Effect of poloxamer 188 on collateral blood flow, myocardial infarct size, and left ventricular function in a canine model of prolonged (3-hour) coronary occlusion and reperfusion
115. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study
116. Radiographic blood pool contrast agents for vascular and tumor imaging with projection radiography and computed tomography
117. Effect of pluronic-F68 on the development of tumor metastasis
118. Poloxamer 188 as vehicle for injectable diazepam
119. Availability of drugs in the presence of surface-active agents. II. Effects of some oxyethylene oxypropylene polymers on the biological activity of hexetidine
120. Availability of drugs in the presence of surface-active agents. I. Critical micelle concentrations of some oxyethylene oxypropylene polymers
121. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo
122. Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice
123. Activity of poloxamer CRL-1072 against drugsensitive and resistant strains of Mycobacterium tuberculosis in macrophages and in mice
124. CRL-1072 enhances antimycobacterial activity of human macrophages through interleukin-8
125. Effect ofpoloxamer CRL-1072 on drug uptake and nitric-oxide-mediated killing of Mycobacterium avium by macrophages
126. Immunoendocrine modulation and stimulation of hematopoiesis with the ionophore copolymer T150R1
127. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials
128. Phase diagrams and aggregation behavior of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) triblock copolymers in aqueous solutions
129. Structural polymorphism of amphiphilic block copolymers in mixtures with water and oil: Comparison with solvent-free block copolymers and surfactant systems
130. On the theory of lower critical solution points in hydrogen-bonded mixtures
131. Molecular modeling of micelle formation and solubilization in block copolymer micelles. 2. Lattice theory for monomers with internal degrees of freedom
132. Molecular modeling of micelle formation and solubilization in block copolymer micelles. 1. A self-consistent mean-field lattice theory
133. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solution. The influence of relative block size
134. Micellization of poly(ethylene oxide)-poly(propylene oxide) block copolymers in aqueous solution
135. Micellization of poly(ethylene oxide)-poly(propylene oxide) block copolymers in aqueous solution: Effect of polymer impurities
136. Block copolymer self-assembly in selective solvents: Theory of solubilization in spherical micelles
137. Light scattering study on the effect of polymer composition on the structural properties of PEO-PPO-PEO micelles
138. Solubilization of hydrocarbons and resulting aggregate shape transitions in aqueous solutions of Pluronic (PEO-PPO-PEO) block copolymers
139. In vitro and in vivo availability of liposomes
140. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: Influence of liposome characteristics
141. Size-dependent extravasation and interstitial localization ofpolyethyleneglycol liposomes in solid tumor-bearing mice
142. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size
143. Uptake by hepatocytes and biliary excretion of intravenously administered polystyrene microspheres in rats
144. Structural study on the micelle formation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer in aqueous solution
145. Micellar sphere-to-rod transition in an aqueous triblock copolymer system. A dynamic light scattering study of translational and rotational diffusion
146. Characterization of a poly(ethylene oxide)-poly(propylene oxide) triblock copolymer (EO27-PO39-EO27) in aqueous solution
147. Strong solubilization of small molecules by triblock-copolymer micelles in selective solvents
148. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols
149. Ion-Induced morphological changes in "crew-cut" aggregates of amphiphilic block copolymers
150. Multiple morphologies and characteristics of "crew-cut" micelle-like aggregates of polystyrene-b-poly(acrylic acid) diblock copolymers in aqueous solutions
151. Multiple morphologies of "crew-cut" aggregates of polystyrene-bpoly(acrylic acid) block copolymers
152. Spontaneous formation of vesicles from complexes of block ionomers and surfactants
153. Polymersomes: Tough vesicles made from diblock copolymers
154. Vesicles formed from a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer in dilute aqueous solution
155. Spontaneous liposome formation induced by grafted poly(ethylene oxide) layers: Theoretical prediction and experimental verification
156. Physical conjugation of (tri-) block copolymers to liposomes toward the construction of sterically stabilized vesicle systems
157. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells
158. Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropyleneb-oxyethylene) solutions
159. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells
160. Interaction ABA block copolymers with ionic surfactants in aqueous solution
161. Surface activity of poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide) copolymers
162. Temperature-dependent micellization in aqueous block copolymer solutions
163. Light-scattering study on the association behavior of triblock polymers of ethylene oxide and propylene oxide in aqueous solution
164. Anomalous micellization behavior and composition heterogeneity of a triblock ABA copolymer of (A) ethylene oxide and (B) propylene oxide in aqueous solution
165. Phase behavior and association properties of poly(oxypropylene)-poly(oxyethylene)-poly(oxypropylene) triblock copolymer in aqueous solution
166. Characterization of a PEO-PPO-PEO block copolymer system
167. Micelle and gel formation in a poly(ethylene oxide)/poly(propylene oxide)/poly(ethylene oxide) triblock copolymer in water solution: Dynamic and static light scattering and oscillatory shear measurements
168. Scanning densitometric and calorimetric studies of poly(ethylene oxide)/poly(propylene oxide)/poly(ethylene oxide) triblock copolymers (poloxamers) in dilute aqueous solution
169. Micellization of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: Thermodynamics of copolymer association
170. Relationship between pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes
171. Temperature effects on structural properties of Pluronic P104 and F108 PEO-PPO-PEO block copolymer solutions
172. Scaling of rheological properties of hydrogels from associating polymers
173. A new class of drug carriers: Micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain
174. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer
175. Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies
176. The influence of three poly(oxyethylene)poly(oxypropylene) surface-active block copolymers on the solubility behavior of indomethacin
177. Kinetic studies on the stability of indomethacin in alkaline aqueous solution containing poly(oxyethylene)poly(oxypropylene) surface-active block copolymers
178. Pluronic surfactants affecting diazepam solubility, compatibility, and adsorption from iv admixture solutions
179. Solubilization of aromatic solutes in block copolymers
180. Comparison of solubilization of hydrocarbons in (PEO-PPO) diblock versus (PEO-PPO-PEO) triblock copolymer micelles
181. Partition coefficients and their uses
182. Interactions of pluronic block copolymers with brain microvessel endothelial cells: Evidence of two potential pathways for drug absorption
183. Poly(styrene-ethylene oxide) block copolymer micelle formation in water: A fluorescence probe study
184. Volatility and solubilization of synthetic fragrances by pluronic P-85
185. Evaluation of partition coefficients of low molecular weight solutes between water and micelles of block copolymer of ethylene oxide based on dialysis kinetics and fluorescence spectroscopy
186. Role of hydrogen bonding in the interaction of hydroxyl-containing substances with Pluronic copolymer micelles
187. Detergent-induced solubilization of cytochrome c oxidase as detected in a novel reconstituted system
188. Detergent binding as a measure of hydrophobic surface area of integral membrane proteins
189. Effect of surfactants on the physical stability of recombinant human growth hormone
190. Structural transitions in micellar solutions of Pluronic P-105 and their effect on the conformation of dissolved Cytochrome C: An electron paramagnetic resonance investigation
191. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses
192. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407
193. Thermal-induced denaturation of two model proteins: Effect of poloxamer 407 on solution stability
194. Inhibition of granulocyte colony stimulating factor (G-CSF) adsorbtion to polyvinyl chloride using a nonionic surfactant
195. Noncovalent complexes of alphachymotrypsin and a block copolymer of ethylene and propylene oxides
196. High-pressure-induced complexes of alpha-chymotrypsin with block copolymers based on ethylene and propoylene oxides
197. Aqueous two-phase systems containing self-associating block copolymers. Partitioning of hydrophilic and hydrophobic biomolecules
198. Transformation ofwater-soluble enzymes into membrane active form by chemical modification
199. Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells
200. Incorporation of chemically modified proteins into liposomes
201. Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture
202. Pluronic micelles as a tool for low-molecular compound vector delivery into a cell: Effect of Staphylococcus aureus enterotoxin B on cell loading with micelle incorporated fluorescent dye
203. Conjugates of proteins with block co-polymers of ethylene and propylene oxides
204. Use of conjugates of bovine serum albumin with poly(alkylene oxide)s for solubilization of riboflavin ester
205. Synthesis and biological activity of the functional block-copolymers based on Pluronic P85-doxorubicin conjugates
206. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents
207. Stabilization of disulfide linkage in drug-polymer-immunoglobulin conjugate by microenvironmental control
208. The reactive polymeric micelle based on an aldehyde-ended poly(ethylene glycol)/poly(lactide) block copolymer
209. Disposition in rats of a polyoxypropylene-polyoxyethylene copolymer used in plasma fractionation
210. A study of labeled pluronic F-68 after intravenous injection into the dog
211. Pharmacokinetics of RheothRx injection in healthy male volunteers
212. Micelles of amphilphilic block copolymers as vehicles for drug delivery
213. Analysis of micelle formation of an adriamycin-conjugated polyethylene glycol-poly(aspartic acid) blockcopolymer by gel permeation chromatography
214. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: In vivo evaluation of anti-cancer activity
215. Polylactidepoly(ethylene glycol) copolymers as drug delivery systems. 1. Characterization of water dispersible micelle-forming systems
216. Physical entrapment of adriamycin in AB block copolymer micelles
217. Development of copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel
218. Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats
219. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers
220. Stabilization and activation of Pluronic micelles for tumor-targeted drug delivery
221. Stabilization of Pluronic P-105 micelles with an interpenetrating network of N,N-diethylacrylamide
222. Control of adriamycin cytotoxic activity using thermally responsive polymeric micelles composed of poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide)
223. Ultrasonic activated drug delivery from Pluronic P-105 micelles
224. Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: Effect of micelle structure and ultrasound on the intracellular drug uptake
225. Factors affecting acoustically triggered release of drugs from polymeric micelles
226. DNA damage induced by micellar-delivered doxorubicin and ultrasound: Comet assay study
227. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma
228. Multidrug resistance-associated protein subfamily transporters and drug resistance
229. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drugresistant cells
230. Elimination of P-gp-mediated multidrug resistance by solubilization in Pluronic micelles
231. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs
232. Reversal of multidrug resistance by surfactants
233. Measurement of cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype
234. Soluto-HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance
235. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity
236. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents
237. Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters
238. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function
239. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance
240. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport
241. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers
242. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers
243. Expression ofmultidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution
244. Molecular mechanisms of multidrug resistance in cancer chemotherapy
245. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems
246. Functional intracellular P-glycoprotein
247. Defective acidification in human breast tumor cells and implications for chemotherapy
248. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein
249. Selective energy depletion and sensitization of multiple drug resistant cancer cells by Pluronic block copolymers
250. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
251. The influence of delta9 -tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen consumption
252. The influence of pluronics and their conjugates with proteins on the rate of oxygen consumption by liver mitochondria and thymus lymphocytes
253. The interaction of nonionic detergents with lipid bilayer membranes
254. Ion transport by heart mitochondria. XXV. Activation of energy-linked K + uptake by non-ionic detergents
255. Uncoupling of oxidative phosphorylation by fatty acids and detergents suppressed by ATP/ADP antiporter inhibitors
256. Effect of a polymeric surfactant on electron transport in HL-60 cells
257. 32p]
258. The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity
259. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism
260. Multidrug resistance: Prospects for clinical management
261. Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers
262. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrugresistant cells
263. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system
264. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells
265. The uses and properties of PEG-linked proteins
266. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers
267. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
268. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
269. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
270. Overexpression of the multidrug resistance gene product in adult rat hepatocytes during primary culture
271. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates
272. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells
273. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2)
274. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
275. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
276. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
277. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone digoxin, and cyclosporin A
278. Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats
279. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells
280. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
281. Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system
282. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: Possible involvement of the monocarboxylic acid transport system
283. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain
284. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
285. Endocytosis: An overview
286. Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: Possible function in insulin processing in the blood-brain barrier
287. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
288. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice
289. Delivery of therapeutic molecules into the CNS
290. Potential applications of polymers in the delivery of drugs to the central nervous system
291. Effect of a nonionic surface-active polymer on passage of hydrocortisone across rat intestine in vitro
292. Dissolution characteristics and oral absorption of digitoxin and digoxin coprecipitates
293. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin
294. Body distribution of camptothecin solid lipid nanoparticles after oral administration
295. Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer
296. Bioavailability of tobramycin after oral delivery in FVB mice using CRL- 1605 copolymer, an inhibitor of P-glycoprotein
297. Direct gene transfer into mouse muscle in vivo
298. Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5
299. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector
300. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
301. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: Anesthetic management and results
302. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
303. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle
304. Block copolymeric biotransport carriers as versatile vehicles for drug delivery
305. Plasmid delivery to muscle: Recent advances in polymer delivery systems
306. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle
307. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates
308. Enhancement of the polycation-mediated DNA uptake and cell transfection with Pluronic P85 block copolymer
309. Evaluation of polyplexes as gene transfer agents
310. Improvement of gene transfer to cervical cancer cell lines using non-viral agents
311. Taking polycation gene delivery systems from in vitro to in vivo
312. Block and graft copolymers and NanoGel copolymer networks for DNA delivery into cell
313. Toxicological evaluation of poloxamer vehicles for intramuscular use
314. Toxicity of Pluronic F-68
315. The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction
316. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats
317. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat
318. Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia
319. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats
320. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3- methylglutaryl CoA reductase in rats
321. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse
322. Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice
323. Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel
324. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin
325. Partitioning of pyrene between "crew cut" block copolymer micelles and H20/DMF solvent mixtures